CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash flows from operating activities:
Net loss	$ (8,198)	$ (20,719)
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued final fee		111
Amortization of debt discount	820	265
Amortization of loan costs		116
Amortization of patents	262	235
Depreciation and amortization	1,234	1,335
Amortization of right-of-use asset	135	174
Write off of inventory	253
Bad debt expense	40	115
Loss on abandoned patents	559	334
Write off of fixed assets	104
Foreign currency transaction (gains) losses	(9,321)	4,225
Stock-based compensation	2,765	3,760
Changes in operating assets and liabilities:
Grants and accounts receivable	423	(1,720)
Inventories	(2,540)	500
Prepaid expenses and other current assets	1,791	(1,352)
Other assets	2	1
Accounts payable and accrued expenses	(706)	(1,808)
Net cash used in operating activities	(12,377)	(14,428)
Cash flows from investing activities:
Purchases of property and equipment	(164)	(284)
Disposal of property and equipment	76
Patent costs	(327)	(385)
Net cash used in investing activities	(415)	(669)
Cash flows from financing activities:
Proceeds from long-term debt	2,478	15,000
Repayment of long-term debt		(5,000)
Payment of final fee		(150)
Payment of loan costs		(698)
Proceeds from rights offering, net	5,392
Cash for exercise of warrants, net	1,439
Equity contributions - net of fees incurred		179
Net cash provided by financing activities	9,309	9,331
Effect of exchange rates on cash	1,490	(85)
Net change in cash, cash equivalents, and restricted cash	(1,993)	(5,851)
Cash, cash equivalents, and restricted cash at beginning of year	9,764	15,615
Cash, cash equivalents, and restricted cash at end of year	7,771	9,764
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	2,082	1,290
Supplemental disclosure of non-cash financing activities:
Warrants issued in connection with modification of long-term debt	$ 627	691
Capital expenditures included in accounts payable		8
Settlement of accrued bonuses with restricted stock units		$ 198